The prognostic value of endogenous hypoxia-related markers for head and neck squamous cell carcinomas treated with ARCON

Radiotherapy and Oncology

Volumn 79, Issue 3, 2006, Pages 288-297

  Jonathan, Ruth A ^a   Wijffels, Karien I E M ^a   Peeters, Wenny ^a   de Wilde, Peter C M ^a   Marres, Henri A M ^a   Merkx, Matthias A W ^a   Oosterwijk, Egbert ^b   van der Kogel, Albert J ^a   Kaanders, Johannes H A M ^a  

^a Department of Radiation Oncology ^*

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Carbonic anhydrase IX; Glucose transporter; Head and neck cancer; Hypoxia; Microvascular density

Indexed keywords

CARBOGEN; CARBONATE DEHYDRATASE IX; CD34 ANTIGEN; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 3; NICOTINAMIDE;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; HYPOXIA; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MICROVASCULATURE; NECROSIS; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; TUMOR BIOPSY; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; ANOXIA; ANTIGENS, NEOPLASM; CARBON DIOXIDE; CARBONIC ANHYDRASES; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE II AS TOPIC; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; GLUCOSE TRANSPORTER TYPE 1; GLUCOSE TRANSPORTER TYPE 3; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NIACINAMIDE; OXYGEN; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RADIATION DOSAGE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 33746265277     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2006.04.008     Document Type: Article

References (51)

1. International Union Against Cancer. TNM classification of malignant tumours. 4th ed (1992), UICC, Geneva
2. Airley R., Loncaster J., Davidson S., et al. Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clin Cancer Res 7 (2001) 928-934
3. Airley R.E., Loncaster J., Raleigh J.A., et al. GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: relationship to pimonidazole binding. Int J Cancer 104 (2003) 85-91
4. Artese L., Rubini C., Ferrero G., Fioroni M., Santinelli A., and Piattelli A. Microvessel density (MVD) and vascular endothelial growth factor expression (VEGF) in human oral squamous cell carcinoma. Anticancer Res 21 (2001) 689-695
5. Baer S., Casaubon L., Schwartz M.R., Marcogliese A., and Younes M. Glut3 expression in biopsy specimens of laryngeal carcinoma is associated with poor survival. Laryngoscope 112 (2002) 393-396
6. Brewer C.A., Liao S.Y., Wilczynski S.P., et al. A study of biomarkers in cervical carcinoma and clinical correlation of the novel biomarker MN. Gynecol Oncol 63 (1996) 337-344
7. Buffa F.M., Bentzen S.M., Daley F.M., et al. Molecular marker profiles predict locoregional control of head and neck squamous cell carcinoma in a randomized trial of continuous hyperfractionated accelerated radiotherapy. Clin Cancer Res 10 (2004) 3745-3754
8. Bui M.H., Seligson D., Han K.R., et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 9 (2003) 802-811
9. Evans S.M., Hahn S., Pook D.R., et al. Detection of hypoxia in human squamous cell carcinoma by EF5 binding. Cancer Res 60 (2000) 2018-2024
10. Flier J.S., Mueckler M., McCall A.L., and Lodish H.F. Distribution of glucose transporter messenger RNA transcripts in tissues of rat and man. J Clin Invest 79 (1987) 657-661
11. Giatromanolaki A., Koukourakis M.I., Sivridis E., et al. Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res 61 (2001) 7992-7998
12. Haber R.S., Rathan A., Weiser K.R., et al. GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis. Cancer 83 (1998) 34-40
13. Hedley D., Pintilie M., Woo J., et al. Carbonic anhydrase IX expression, hypoxia, and prognosis in patients with uterine cervical carcinomas. Clin Cancer Res 9 (2003) 5666-5674
14. Hockel M., and Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93 (2001) 266-276
15. Hoogsteen I.J., Marres H.A., Wijffels K.I., et al. Colocalization of carbonic anhydrase 9 expression and cell proliferation in human head and neck squamous cell carcinoma. Clin Cancer Res 11 (2005) 97-106
16. Hoskin P.J., Sibtain A., Daley F.M., Saunders M.I., and Wilson G.D. The immunohistochemical assessment of hypoxia, vascularity and proliferation in bladder carcinoma. Radiother Oncol 72 (2004) 159-168
17. Hoskin P.J., Sibtain A., Daley F.M., and Wilson G.D. GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON. Br J Cancer 89 (2003) 1290-1297
18. Hussain S.A., Palmer D.H., Ganesan R., et al. Carbonic anhydrase IX, a marker of hypoxia: correlation with clinical outcome in transitional cell carcinoma of the bladder. Oncol Rep 11 (2004) 1005-1010
19. Janot F., Klijanienko J., Russo A., et al. Prognostic value of clinicopathological parameters in head and neck squamous cell carcinoma: a prospective analysis. Br J Cancer 73 (1996) 531-538
20. Kaanders J.H., Pop L.A., Marres H.A., et al. ARCON: experience in 215 patients with advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 52 (2002) 769-778
21. Kaanders J.H., Wijffels K.I., Marres H.A., et al. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res 62 (2002) 7066-7074
22. Kang S.S., Chun Y.K., Hur M.H., et al. Clinical significance of glucose transporter 1 (GLUT1) expression in human breast carcinoma. Jpn J Cancer Res 93 (2002) 1123-1128
23. Kato H., Takita J., Miyazaki T., et al. Glut-1 glucose transporter expression in esophageal squamous cell carcinoma is associated with tumor aggressiveness. Anticancer Res 22 (2002) 2635-2639
24. Kawamura T., Kusakabe T., Sugino T., et al. Expression of glucose transporter-1 in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival. Cancer 92 (2001) 634-641
25. Koukourakis M.I., Giatromanolaki A., Sivridis E., and Fezoulidis I. Cancer vascularization: implications in radiotherapy?. Int J Radiat Oncol Biol Phys 48 (2000) 545-553
26. Koukourakis M.I., Giatromanolaki A., Sivridis E., et al. Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. Clin Cancer Res 7 (2001) 3399-3403
27. Kunkel M., Reichert T.E., Benz P., et al. Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer 97 (2003) 1015-1024
28. Lal A., Peters H., St Croix B., et al. Transcriptional response to hypoxia in human tumors. J Natl Cancer Inst 93 (2001) 1337-1343
29. Loncaster J.A., Harris A.L., Davidson S.E., et al. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 61 (2001) 6394-6399
30. Mayer A., Hockel M., Wree A., and Vaupel P. Microregional expression of glucose transporter-1 and oxygenation status: lack of correlation in locally advanced cervical cancers. Clin Cancer Res 11 (2005) 2768-2773
31. Mineta H., Miura K., Takebayashi S., et al. Prognostic value of glucose transporter 1 expression in patients with hypopharyngeal carcinoma. Anticancer Res 22 (2002) 3489-3494
32. Murray J.D., Carlson G.W., McLaughlin K., et al. Tumor angiogenesis as a prognostic factor in laryngeal cancer. Am J Surg 174 (1997) 523-526
33. Nordsmark M., Bentzen S.M., Rudat V., et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 77 (2005) 18-24
34. Olive P.L., Aquino-Parsons C., MacPhail S.H., et al. Carbonic anhydrase 9 as an endogenous marker for hypoxic cells in cervical cancer. Cancer Res 61 (2001) 8924-8929
35. Olive P.L., Durand R.E., Raleigh J.A., Luo C., and Aquino-Parsons C. Comparison between the comet assay and pimonidazole binding for measuring tumour hypoxia. Br J Cancer 83 (2000) 1525-1531
36. Pignataro L., Carboni N., Midolo V., et al. Clinical relevance of microvessel density in laryngeal squamous cell carcinomas. Int J Cancer 92 (2001) 666-670
37. Raleigh J.A., Chou S.C., Bono E.L., Thrall D.E., and Varia M.A. Semiquantitative immunohistochemical analysis for hypoxia in human tumors. Int J Radiat Oncol Biol Phys 49 (2001) 569-574
38. Reisser C., Eichhorn K., Herold-Mende C., Born A.I., and Bannasch P. Expression of facilitative glucose transport proteins during development of squamous cell carcinomas of the head and neck. Int J Cancer 80 (1999) 194-198
39. Rofstad E.K. Microenvironment-induced cancer metastasis. Int J Radiat Biol 76 (2000) 589-605
40. Said H.M., Katzer A., Flentje M., and Vordermark D. Response of the plasma hypoxia marker osteopontin to in vitro hypoxia in human tumor cells. Radiother Oncol 76 (2005) 200-205
41. Salmon H.W., and Siemann D.W. Utility of 19F MRS detection of the hypoxic cell marker EF5 to assess cellular hypoxia in solid tumors. Radiother Oncol 73 (2004) 359-366
42. Sly W.S., and Hu P.Y. Human carbonic anhydrases and carbonic anhydrase deficiencies. Annu Rev Biochem 64 (1995) 375-401
43. Sorensen B.S., Hao J., Overgaard J., et al. Influence of oxygen concentration and pH on expression of hypoxia induced genes. Radiother Oncol 76 (2005) 187-193
44. Troost E.G., Bussink J., Kaanders J.H., et al. Comparison of different methods of CAIX quantification in relation to hypoxia in three human head and neck tumor lines. Radiother Oncol 76 (2005) 194-199
45. Wertheimer E., Sasson S., Cerasi E., and Ben-Neriah Y. The ubiquitous glucose transporter GLUT-1 belongs to the glucose-regulated protein family of stress-inducible proteins. Proc Natl Acad Sci USA 88 (1991) 2525-2529
46. Wijffels K.I., Kaanders J.H., Rijken P.F., et al. Vascular architecture and hypoxic profiles in human head and neck squamous cell carcinomas. Br J Cancer 83 (2000) 674-683
47. Wykoff C.C., Beasley N.J., Watson P.H., et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 60 (2000) 7075-7083
48. Yaromina A., Holscher T., Eicheler W., et al. Does heterogeneity of pimonidazole labelling correspond to the heterogeneity of radiation-response of FaDu human squamous cell carcinoma?. Radiother Oncol 76 (2005) 206-212
49. Younes M., Brown R.W., Stephenson M., Gondo M., and Cagle P.T. Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer 80 (1997) 1046-1051
50. Younes M., Juarez D., Lechago L.V., and Lerner S.P. Glut 1 expression in transitional cell carcinoma of the urinary bladder is associated with poor patient survival. Anticancer Res 21 (2001) 575-578
51. Zhang J.Z., Behrooz A., and Ismail-Beigi F. Regulation of glucose transport by hypoxia. Am J Kidney Dis 34 (1999) 189-202